Literature DB >> 18405601

[Investigation of gene expression profiles in patients with blood stasis syndrome].

Xiao-juan Ma1, Hui-jun Yin, Ke-ji Chen.   

Abstract

OBJECTIVE: To investigate the differential gene expression profiles in patients with blood stasis syndrome by oligonucleotide microarray technique.
METHODS: Sixteen patients with blood stasis syndrome were divided into patients with coronary heart disease (CAD) (n=8) and non-CAD patients (n=8) by using coronary angiography. The sex- and age-matched eight healthy persons were enrolled as control group. Venous bloods were collected for extracting RNA. Test-3 chip was first employed to examine the quality of samples. Then the samples were hybridized with Affymetrix U133 Plus 2.0 array to compare the gene expression profiles among the three groups. Gene-array scanner and gene chip operating software were applied to screen hybridization signals and analyze gene expression respectively. Based on the comparison of the three groups of samples, the differential genes related with blood stasis syndrome were analyzed by Gene Ontology (GO) and pathway, and confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR).
RESULTS: Forty-eight differential genes were found being associated with blood stasis syndrome, including 26 up-regulated genes and 22 down-regulated genes. Five of the forty-eight genes (10.4%) were related to inflammatory reaction and immune response through the GO analysis. In the pathway analysis, five of ten significant pathways were referred to inflammation and immune response. The results of real-time RT-PCR proved the accuracy of the gene chip.
CONCLUSION: Inflammatory- and immune-related genes have a remarkable predominance in blood stasis syndrome gene expression profiles, which may explain the function of inflammation and immune response in the occurrence and development of blood stasis syndrome.

Entities:  

Mesh:

Year:  2008        PMID: 18405601     DOI: 10.3736/jcim20080406

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  7 in total

1.  The diagnostic criteria of blood-stasis syndrome: considerations for standardization of pattern identification.

Authors:  Si-ming Li; Hao Xu; Ke-ji Chen
Journal:  Chin J Integr Med       Date:  2014-03-07       Impact factor: 1.978

2.  Co-expression network analysis of Down's syndrome based on microarray data.

Authors:  Jianping Zhao; Zhengguo Zhang; Shumin Ren; Yanan Zong; Xiangdong Kong
Journal:  Exp Ther Med       Date:  2016-06-17       Impact factor: 2.447

Review 3.  Integrative Western and chinese medicine on coronary heart disease: where is the orientation?

Authors:  Siming Li; Hao Xu
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-19       Impact factor: 2.629

4.  Susceptible gene of stasis-stagnation constitution from genome-wide association study related to cardiovascular disturbance and possible regulated traditional Chinese medicine.

Authors:  Kuo-Chin Huang; Hung-Jin Huang; Ching-Chu Chen; Chwen-Tzuei Chang; Tzu-Yuan Wang; Rong-Hsing Chen; Yu-Chian Chen; Fuu-Jen Tsai
Journal:  BMC Complement Altern Med       Date:  2015-07-14       Impact factor: 3.659

5.  Clinical Applications of Omics Technologies on ZHENG Differentiation Research in Traditional Chinese Medicine.

Authors:  Ya-Nan Song; Gui-Biao Zhang; Yong-Yu Zhang; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-18       Impact factor: 2.629

6.  High-throughput metabolomics used to identify potential therapeutic targets of Guizhi Fuling Wan against endometriosis of cold coagulation and blood stasis.

Authors:  Xiu-Hong Wu; Chuang Zhao; Ai-Hua Zhang; Jin-Qi Zhang; Xu Wang; Xiao-Lan Sun; Ze Sun; Xi-Jun Wang
Journal:  RSC Adv       Date:  2018-05-24       Impact factor: 4.036

7.  Network-based biomarkers for cold coagulation blood stasis syndrome and the therapeutic effects of shaofu zhuyu decoction in rats.

Authors:  Shulan Su; Jinao Duan; Wenxia Cui; Erxing Shang; Pei Liu; Gang Bai; Sheng Guo; Dawei Qian; Yuping Tang
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-21       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.